Pharmaceutical composition for external use

Abstract

A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) crotamiton. (−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile

What is claimed is: 
     
         1 . A pharmaceutical composition for external use, comprising:
 i) (R)-luliconazole represented by the following structural formula (1) and/or a salt thereof; and   ii) crotamiton at a concentration of 0.1 to 40% by mass   
       
         
           
           
               
               
           
         
       
       (−)-(E)-[(4R)-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile Structural formula (1). 
     
     
         2 . A pharmaceutical composition according to  claim 1 , wherein the composition comprises crotamiton in an amount of 1 to 10% by mass of the composition. 
     
     
         3 . A pharmaceutical composition according to  claim 1 , wherein the composition comprises (R)-luliconazole in an amount of 0.5 to 15% by mass of the composition. 
     
     
         4 . A pharmaceutical composition according to  claim 1 , wherein the composition further comprises ethanol. 
     
     
         5 . A pharmaceutical composition according to  claim 4 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition. 
     
     
         6 . A method of treating mycotic disease comprising externally administering the composition of  claim 1  to an individual in need of treatment. 
     
     
         7 . A method according to  claim 6 , wherein the mycotic disease is foot trichophytosis, trichophytosis corporis or trichophytosis on a hard keratin portion. 
     
     
         8 . A method according to  claim 6 , wherein the mycotic disease is athlete's foot. 
     
     
         9 . A method according to  claim 6 , wherein the mycotic disease is onychomycosis. 
     
     
         10 . A method according to  claim 6 , wherein the mycotic disease is a mycotic disease of a nail. 
     
     
         11 . A method according to  claim 6 , wherein the mycotic disease is dermatomycosis. 
     
     
         12 . A pharmaceutical composition according to  claim 2 , wherein the composition comprises (R)-luliconazole in an amount of 0.5 to 15% by mass of the composition. 
     
     
         13 . A pharmaceutical composition according to  claim 2 , wherein the composition further comprises ethanol. 
     
     
         14 . A pharmaceutical composition according to  claim 13 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition. 
     
     
         15 . A pharmaceutical composition according to  claim 3 , wherein the composition further comprises ethanol. 
     
     
         16 . A pharmaceutical composition according to  claim 15 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition. 
     
     
         17 . A pharmaceutical composition according to  claim 12 , wherein the composition further comprises ethanol. 
     
     
         18 . A pharmaceutical composition according to  claim 17 , wherein the composition comprises ethanol in amount of 50 to 90% by mass of the composition. 
     
     
         19 . A pharmaceutical composition for external use, consisting essentially of:
 i) (R)-(−)-(E)-[4-(2,4-dichlorophenyl)-1,3-dithiolan-2-iliden]-1-imidazolyl acetonitrile and/or a salt thereof; and   ii) crotamiton at a concentration of 0.1 to 40% by mass.   
     
     
         20 . The pharmaceutical composition of any one of  claims 1 ,  2 ,  3 ,  4 ,  12 , or  14 , wherein the pharmaceutical composition is formulated as a lotion.